Introduction
============

There are concerns that prophylactic and metaphylactic uses of antimicrobial drugs in food animal production increase antimicrobial resistance with potential adverse effects on human health ([@bib18]; [@bib30]). Animal agriculture industries are being encouraged to reduce the use of all types of antimicrobial drugs, to find nonantimicrobial alternatives for nontherapeutic needs, and to optimize animal health through management approaches.

One area of focus in the dairy and beef industry is calves on calf ranches being reared as dairy heifer replacements or bull calves for beef. A key aspect to successfully rearing these animals is to ensure adequate intake of colostrum to support the animal\'s passive immunity. Calves with adequate passive transfer of immunity have lower mortality and morbidity and fewer antibiotic treatments compared with animals with failure of passive transfer ([@bib6]). Despite the general knowledge of the importance of feeding colostrum to the neonatal calf, calves arrive at calf ranches with suboptimal serum immunoglobulin levels ([@bib8]; [@bib7]; [@bib23]). To address this problem, it is a widely accepted practice to feed antimicrobials to preweaned calves ([@bib10]; [@bib14]; [@bib19]; [@bib27]).

To properly provide support to systemic immunity, good quality colostrum needs to be administered in appropriate volumes as early as possible within the first 24 h after birth ([@bib35]). However, there is evidence that antibodies remaining in the gut lumen after colostrum feeding also provide local immunity against enteric viral infections and diarrhea caused by bacterial enterotoxins and may enhance intestinal villus development ([@bib31], [@bib32]; [@bib29]; [@bib11]). Given this observation, in the absence of properly administered colostrum, it is possible that a colostrum supplement could provide local gut immunity and decrease the need for supplemental antimicrobials in colostrum-deprived calves. The objective of this study (a multisite clinical trial) was to determine the effect of oral IgG supplementation on preweaned calf mortality, morbidity, weight gain, and feed intake. The hypothesis was that oral IgG supplementation during the early preweaning period decreases calf mortality and morbidity.

Materials and Methods
=====================

Study Sites
-----------

Colostrum supplementation trials were performed at 3 California calf ranches raising dairy-source calves: bull calves reared for beef (ranch A), mixed bull beef and heifer replacements (ranch B), and bull beef (ranch C). The studies were conducted between October 2005 and September 2006. On ranch A, the calves were fed milk replacer \[22% CP and 18% crude fat (**CF**)\] medicated with neomycin and tetracycline. On ranch B, the calves were fed milk replacer (22% CP and 22% CF) medicated with neomycin and tetracycline for the first 2 wk; thereafter, the calves received pasteurized hospital milk medicated with tetracycline. On ranch C, the calves were fed nonmedicated milk replacer (22% CP and 18% CF). On all 3 ranches, it was standard procedure for calves to receive a colostrum supplement at the first feeding (usually the afternoon) following delivery to the ranch. Calves were bottle-fed 1.89 L of milk replacer or milk twice daily. Fresh water and fresh calf starter grain in buckets were administered daily.

Study Design and On-Farm Procedures
-----------------------------------

A minimum of ninety 1- to 3-d-old Holstein calves were enrolled at each calf ranch and randomly allocated to 1 of 3 treatment groups: colostrum supplement (**CS**), placebo supplement (**PS**), or unsupplemented control (**UC**). The assumptions for calculating the sample size were type I error = 0.10, type II error = 0.10, detecting a difference of a mean 5 diarrhea days for UC and PC calves compared with 3.5 d for CS calves, and a sample standard deviation of 2 d. The estimated sample size was inflated to allow for a 15% loss to follow-up.

The CS group received 70 g of dried colostrum powder (Calves Choice Total Bronze, Saskatoon Colostrum Co. Ltd., Saskatchewan, Canada), containing 10 g of IgG in each of 2 daily milk replacer meals for 14 d. The colostrum powder contained 45% CP, 26% CF, 13% lactose, 5% ash, and gross energy of 5.9 Mcal/kg of DM corresponding to 231 kcal/70 g of powder. The PS group similarly received 70 g of milk replacer powder, matched to the colostrum supplement, with 45% CP and 26% CF (Calva Products Inc., Acampo, CA), but did not contain IgG. The UC group received no addition to their milk replacer formula. The supplements were mixed in 2.4 dL of warm water and added to bottles before addition of the milk replacer powder. Study personnel were in charge of all feedings.

Calves were independently evaluated daily by study personnel blinded to calf treatment group. They were evaluated for morbidity, which included fecal consistency, attitude, hydration, and respiratory scores ([@bib6]). If any abnormalities were noted, then a rectal temperature was obtained. All treatments in the first 28 d were performed and recorded by study personnel based on treatment protocols agreed upon with farm management. Each course of antimicrobial treatment was 3 d or longer, in accordance with label instructions or the farm-specific treatment protocols. Diarrheal disease was defined as watery and/or bloody feces. Respiratory scores were 1 for nasal discharge, 2 for coughing, 3 for heavy thoracic breathing, and 4 for abdominal breathing. Respiratory disease was defined as a score 3 or 4. All calves with diarrhea or respiratory disease were treated with antimicrobial drugs as described above. All calves were weighed 3 times during the trial on a mechanical scale (with accuracy to the nearest 1 lb.): at entry into the trial, 28 d on the farm, and at weaning (60 d). Feed consumption (milk and grain) were recorded for 28 d. After 28 d, management of the calves was taken over by the calf ranch. Study personnel returned to measure weaning weight.

Passive Transfer of Immunity
----------------------------

Blood samples from all calves were collected on the day after arrival (d 2) at the ranch. On ranch A, blood samples were also collected on d 7 to evaluate if colostrum supplementation modified the serum IgG levels in the calves. Serum IgG levels were determined using a commercial radial immunodiffusion assay (Immuno-check, VMRD, Pullman, WA).

Data Analysis
-------------

Health and treatment data were recorded in a spreadsheet program (Excel, Microsoft Corp., Redmond, WA) and analyzed using a statistical software program (version 9.1, SAS Institute Inc., Cary, NC). Ninety percent confidence intervals were calculated for all main effect estimates. Interactions between all main effects were tested and retained in the models if their *P*-values were ≤0.1.

### Passive Transfer of Immunity

Passive transfer of immunity status was classified as failure of passive transfer (**FPT**) for IgG ≤350 mg/dL, partial failure of passive transfer (**PFPT**) for values from 351 to 999 mg/dL, and adequate passive transfer (**APT**) for IgG ≥1,000 mg/dL ([@bib34]; [@bib6]).

### Arrival Weights

Calf weights taken when the calves were initially processed on arrival to the ranch were classified as low for weights ≤38.5 kg (80 lb.), mid for weights between 38.6 and 44.9 kg (80 to 100 lb.), and high for weights ≥45 kg (100 lb.)

### Mortality

Mortality in calves during the first 28 d was evaluated using univariate Kaplan-Meier survival plots. The Cox proportional hazard model was used for multivariate assessment of mortality. Proportionality of hazards was assessed by plotting ln\[--ln(survival)\] against ln(calf-days), including time-dependent interactions for each of the predictive variables in the proportional hazard model and using a linear proportionality test ([@bib3]). Hazard rate ratios and 90% confidence intervals for the main effect (treatment group) and each covariate (calf ranch, arrival weight category, and serum IgG category) were determined ([@bib24]).

### Morbidity

The percentage of days that the calves had diarrhea and were treated for diarrhea was calculated. The number of days a calf was observed with diarrhea during the days at risk conditional on treatment group was assessed using a negative binomial model ([@bib2]). Treatment group was the main effect evaluated and confounding variables included calf ranch, calf arrival weight category, and calf IgG category. The days to first antimicrobial treatment for diarrhea conditional on treatment group, including the same confounding variables, was evaluated using the survival analysis approach described previously for mortality. Difference in respiratory morbidity (based on an ordinal severity scale) between treatment groups was assessed using the Jonckheere-Terpstra nonparametric test for trend ([@bib22])

### ADG and Grain Intake

A general linear model calculating least squares means was used to compare treatment differences in ADG up to 28 d of age and at weaning (60 d). Least squares mean estimates and 90% confidence intervals were calculated for the main effect of treatment group and the covariates of calf ranch, arrival weight category, and serum IgG category. Grain consumption was measured daily for 28 d and the average daily intake was calculated. The same main effect and covariate set used for ADG were used to evaluate grain intake.

Results
=======

The 3 clinical trials included 273 calves: 91 at ranch A, 90 at ranch B, and 92 at ranch C. Calves that died before obtaining the blood sample for serum IgG evaluation on the day after arrival (3 calves on ranch C) were excluded from the study

Passive Transfer of Immunity and Birth Weights
----------------------------------------------

Failure of passive transfer was common in the study calves, with 19, 43, and 38% in IgG categories FPT, PFPT, and APT, respectively ([Table 1](#tbl1){ref-type="table"} ). On ranch A, the serum IgG of calves was not significantly different at d 7 between calves in the 3 treatment groups (data not shown). The calves were categorized into arrival weight categories; 31% low, 41% mid, and 29% high ([Table 1](#tbl1){ref-type="table"}).Table 1Descriptive statistics of serum IgG category and arrival weights stratified by treatment group from 3 field trials evaluating the efficacy of feeding a colostrum supplement in milk replacer for 14 d to preweaned calvesTreatment group[1](#tbl1fn1){ref-type="table-fn"}Serum IgG, mg/dLIgG category,[2](#tbl1fn2){ref-type="table-fn"} n (ndead)Arrival weight, kgWeight category,[3](#tbl1fn3){ref-type="table-fn"} nMeanSDTotalAPTPFPTFPTMeanSDLowMidHighCS1,1471,13892 (13)34 (1)44 (6)14 (6)41.35.7363224PS1,2101,21091 (13)34 (1)37 (4)20 (8)425.4224326UC1,3521,71190 (12)36 (0)36 (5)18 (7)41.85.3263628Total1,2361,372273 (38)104 (2)117 (15)52 (21)41.75.48411178[^1][^2][^3]

Mortality
---------

Mortality rates over the first 28 d of the trials were 7.7, 7.8, and 26.1% on ranches A, B, and C, respectively. The proportional hazard model indicated that there was no significant influence of colostrum supplement on mortality ([Table 2](#tbl2){ref-type="table"} ). The hazard of dying in calves with FPT or PFPT was 26 or 6 times greater, respectively, than in calves with APT.Table 2Results from a multivariate proportional hazards model of mortality in calves during the first 28 d of life from 3 field trials (ranches A, B, and C) evaluating the efficacy of feeding a colostrum supplement in milk replacer for 14 d to preweaned calvesVariableLevelHazard ratio90% CI[1](#tbl2fn1){ref-type="table-fn"}Wald\'s *P*-valueLowerUpperTreatment group[2](#tbl2fn2){ref-type="table-fn"}CS1.020.521.980.96PS0.860.441.690.72UCReference---------Weight category[3](#tbl2fn3){ref-type="table-fn"}Low0.960.442.070.93Mid0.710.331.520.46HighReference---------Serum IgG status[4](#tbl2fn4){ref-type="table-fn"}FPT26.227.6090.38\<0.01PFPT5.881.6820.520.02APTReference---------Calf ranchA0.290.140.60\<0.01B0.440.210.950.08CReference---------[^4][^5][^6][^7]

Morbidity
---------

Over the 28-d trial period, the overall percentage of days that diarrhea was observed was 8.8%, with the colostrum-supplemented group having the lowest percentage of diarrhea days ([Table 3](#tbl3){ref-type="table"} ). From the multivariate negative binomial model assessing number of diarrhea days, calves receiving the colostrum supplement had fewer diarrheal days compared with unsupplemented controls (relative risk = 0.61; 90% CI = 0.49--0.78; [Table 4](#tbl4){ref-type="table"} ). There was no difference in the risks of diarrhea between placebo supplemented and unsupplemented control calves (relative risk = 1.07; 90% CI = 0.86--1.32). Calves with FPT and PFPT had increased risk for diarrhea compared with calves with APT. Low- and mid-weight calves also tended to have greater risk for diarrhea than high-arrival-weight calves.Table 3Descriptive statistics of ADG, total calf study days (total days), number (%) of days calves observed with diarrhea and respiratory disease, number (%) of days calves treated with antimicrobials (treatment days), and average grain and milk intake stratified by treatment group from 3 field trials evaluating the efficacy of feeding a colostrum supplement in milk replacer for 14 d to preweaned calvesTreatment group[1](#tbl3fn1){ref-type="table-fn"}ADG, kgTotal daysDisease daysTreatment days (%)Feed consumption[2](#tbl3fn2){ref-type="table-fn"}d 28d 60Diarrhea days, n (%)Resp[3](#tbl3fn3){ref-type="table-fn"} days, n (%)Grain, kga.m.milk, Lp.m.milk, LMeanSDMeanSDCS0.280.170.550.22,210147 (6.1)24 (1.0)196 (8.2)0.231.871.85PS0.230.180.510.162,096255 (10.7)35 (1.46)293 (12.3)0.231.861.86UC0.220.150.520.182,075226 (9.7)17 (0.74)247 (10.6)0.191.871.82Total0.240.170.520.187,118628 (8.8)76 (1.06)736 (10.3)0.221.871.84[^8][^9][^10]Table 4Results from a multivariate negative binomial model of total diarrhea days observed in calves during the first 28 d of life from 3 field trials (ranches A, B, and C) evaluating the efficacy of feeding a colostrum supplement in milk replacer for 14 d to preweaned calvesVariableLevelRisk ratio90% CI[1](#tbl4fn1){ref-type="table-fn"}*P*-valueLowerUpperTreatment group[2](#tbl4fn2){ref-type="table-fn"}CS0.610.490.78\<0.01PS1.070.861.320.61UCReference---------Weight category[3](#tbl4fn3){ref-type="table-fn"}Low1.541.182.00\<0.01Mid1.341.061.690.04HighReference---------Serum IgG category[4](#tbl4fn4){ref-type="table-fn"}FPT2.882.223.71\<0.01PFPT1.851.502.28\<0.01APTReference---------Calf ranchA1.701.352.14\<0.01B1.551.201.99\<0.01CReference---------[^11][^12][^13][^14]

Overall, calves were treated with antimicrobials (primarily for diarrheal disease) for approximately 10% of the total study calf-days ([Table 3](#tbl3){ref-type="table"}). Calves in the colostrum-supplemented group had the lowest percentage of treatment days. The Kaplan-Meier plot indicated significant differences (Wilcoxon test equality of strata: χ^2^  = 7.53; *P*  = 0.02) in days to first treatment of diarrhea between the groups ([Figure 1](#fig1){ref-type="fig"} ). The multivariate proportional hazard model controlling for other factors similarly showed that calves in the colostrum supplemented group had a significant increase in days to antimicrobial treatment (hazard ratio = 0.57; 90% CI = 0.38--0.87) compared with unsupplemented control calves ([Table 5](#tbl5){ref-type="table"} ). The risk for being treated with antimicrobials was increased for low-weight calves (compared with high-weight calves) and calves with FPT and PFPT (compared with APT calves).Figure 1Kaplan-Meier plot showing days to first treated diarrhea stratified by treatment group in 3 field trials evaluating the efficacy of feeding a colostrum supplement in milk replacer for 14 d to preweaned calves (Wilcoxon test of equality of strata, χ^2^ = 7.53; *P* = 0.02).Table 5Results from a multivariate proportional hazards model of the days to first antimicrobial treatment from 3 field trials (ranches A, B, and C) evaluating the efficacy of feeding a colostrum supplement in milk replacer for 14 d to preweaned calvesVariableLevelHazard ratio90% CI[1](#tbl5fn1){ref-type="table-fn"}Wald\'s *P*-valueLowerUpperTreatment group[2](#tbl5fn2){ref-type="table-fn"}CS0.570.380.870.03PS1.100.771.580.67UCReference---------Weight category[3](#tbl5fn3){ref-type="table-fn"}Low2.171.353.480.01Mid1.601.032.480.08HighReference---------Serum IgG status[4](#tbl5fn4){ref-type="table-fn"}FPT3.732.375.87\<0.01PFPT1.891.262.820.01APTReference---------Calf ranchA0.970.661.430.9B1.240.811.910.4CReference---------[^15][^16][^17][^18]

Respiratory disease including heavy respiration or abdominal breathing was present in 1% of the observation calf-days ([Table 3](#tbl3){ref-type="table"}). There was no significant difference among treatment groups for respiratory scores (*P *= 0.25).

ADG and Grain Intake
--------------------

Calves in the colostrum treatment group had a significantly greater ADG to 28 d of age than the calves in the unsupplemented control group ([Table 6](#tbl6){ref-type="table"} ). Calves with FPT had a significantly lower ADG compared with APT calves. Low-weight calves had greater ADG during the first 28 d of life than heavier calves. Calves on ranches A and B gained more weight than calves on ranch C. At weaning (60 d), the only factors significantly affecting weight gain were IgG status and calf ranch ([Table 7](#tbl7){ref-type="table"} ). The average daily grain intake for the first 28 d of life was greater in calves receiving the 14-d colostrum or placebo supplement compared with the unsupplemented calves, in heavier weight calves, and in calves with PFPT or APT compared with FPT ([Table 8](#tbl8){ref-type="table"} ). There were significant differences in grain consumption between animals on the 3 ranches.Table 6Results from a multivariate GLM[1](#tbl6fn1){ref-type="table-fn"} modeling 28-d ADG in 3 field trials (ranches A, B, and C) evaluating the efficacy of feeding a colostrum supplement in milk replacer for 14 d to preweaned calves (n = 235)VariableLevelLSM Estimate,[2](#tbl6fn2){ref-type="table-fn"} kg*P*-value90% CI[3](#tbl6fn3){ref-type="table-fn"}LowerUpperTreatment group[4](#tbl6fn4){ref-type="table-fn"}CS0.240.040.220.27PS0.220.390.190.25UC0.20Reference0.170.23Serum IgG category[5](#tbl6fn5){ref-type="table-fn"}FPT0.15\<0.010.110.20PFPT0.240.120.210.26APT0.27Reference0.250.29Weight category[6](#tbl6fn6){ref-type="table-fn"}Low0.27\<0.010.240.30Mid0.23\<0.010.200.25High0.16Reference0.130.20Calf ranchA0.33\<0.010.310.36B0.12\<0.010.100.16C0.21Reference0.180.24[^19][^20][^21][^22][^23][^24]Table 7Results from a multivariate GLM[1](#tbl7fn1){ref-type="table-fn"} modeling 60-d ADG in 3 field trials (ranches A, B, and C) evaluating the efficacy of feeding a colostrum supplement in milk replacer for 14 d to preweaned calves (n = 176)[2](#tbl7fn2){ref-type="table-fn"}VariableLevelLSM estimate,[3](#tbl7fn3){ref-type="table-fn"} kg*P*-value90% CI[4](#tbl7fn4){ref-type="table-fn"}LowerUpperTreatment group[5](#tbl7fn5){ref-type="table-fn"}CS0.480.440.440.51PS0.440.630.410.48UC0.45Reference0.420.49Serum IgG category[6](#tbl7fn6){ref-type="table-fn"}FPT0.39\<0.010.330.44PFPT0.480.240.450.51APT0.51Reference0.480.54Weight category[7](#tbl7fn7){ref-type="table-fn"}Low0.460.620.420.50Mid0.470.380.440.50High0.44Reference0.410.48Calf ranchA0.63\<0.010.600.66B0.43\<0.010.400.46C0.31Reference0.260.37[^25][^26][^27][^28][^29][^30][^31]Table 8Results from a multivariate GLM[1](#tbl8fn1){ref-type="table-fn"} modeling 28-d average daily grain consumption in 3 field trials (ranches A, B, and C) evaluating the efficacy of feeding a colostrum supplement in milk replacer for 14 d to preweaned calves (n = 235)VariableLevelLSM estimate,[2](#tbl8fn2){ref-type="table-fn"} kg*P*-value90% CI[3](#tbl8fn3){ref-type="table-fn"}LowerUpperTreatment group[4](#tbl8fn4){ref-type="table-fn"}CS0.22\<0.010.190.24PS0.210.020.190.23UC0.17Reference0.150.19Serum IgG category[5](#tbl8fn5){ref-type="table-fn"}FPT0.16\<0.010.120.19PFPT0.220.580.200.23APT0.23Reference0.210.24Weight category[6](#tbl8fn6){ref-type="table-fn"}Low0.17\<0.010.150.19Mid0.200.200.190.22High0.22Reference0.200.25Calf ranchA0.28\<0.010.260.30B0.21\<0.010.190.23C0.10Reference0.080.13[^32][^33][^34][^35][^36][^37]

Discussion
==========

This study indicates that post-gut-closure feeding of a colostrum supplement to calves was effective in reducing both days with diarrhea and associated antimicrobial treatments. Although the colostrum supplement was effective, adequate passive transfer of immunity was the most important predictor of calf health.

Passive Transfer of Immunity
----------------------------

The majority of calves arriving onto these calf ranches had FPT or PFPT, which was the most important predictor of mortality, morbidity, low weight gain, and low grain intake. In addition, there were no interactions between colostrum treatment and FPT for any of the health outcomes. Furthermore, the serum IgG measured on d 7 on ranch A supports previous studies that post-gut-closure feeding of a colostrum supplement will not improve the passive systemic immunity ([@bib33]). Therefore, the critical time to address failure of passive transfer in calf ranch calves is within the first 24 h after birth, and this needs to be addressed at the dairy of origin.

Mortality
---------

There was no detectable difference in mortality between the treatment groups, and, consistent with previous studies, the most important factor associated with mortality was FPT ([@bib16]; [@bib6]). Despite our efforts to develop management approaches to ameliorate the negative impacts of FPT on calf mortality, we have yet to find an effective strategy. The high mortality on ranch C was attributed to a salmonellosis outbreak in the calves during a period of severe heat stress. Several study calves on ranch C had bloody diarrhea, and the calf pathogenic *Salmonella enterica* serovar Newport was recovered from fecal samples from ten 2-wk-old calves and four 4-wk-old calves, as well as from 4 postmortem samples of septicemic calves (A. C. B. Berge, personal communication). The failure to successfully treat these calves for diarrheal and systemic disease is likely due to an interaction between FPT and the virulence of the *Salmonella* Newport serovar, which has been reported as a calf and cow pathogen resulting in high mortality and resistant to the antimicrobials in the treatment protocols ([@bib5]).

Morbidity
---------

Colostrum supplement added to calf milk replacer for the first 14 d of life significantly reduced the number of days the calves had diarrhea and decreased the use of therapeutic antimicrobials in calves. This effect was likely due to the presence of colostral immunoglobulins and not simply a nutritional benefit of colostrum, as this same effect on diarrhea and treatment was not observed in the placebo-supplemented calves. Several clinical studies have demonstrated that colostrum or blood plasma immunoglobulins can provide local immunity against several pathogens associated with calf diarrheal disease such as *Escherichia coli*, rota virus, and corona virus ([@bib1]; [@bib4]; [@bib15]).

The IgG supplement used for our study was pasteurized and spray-dried first-day colostrum. A study feeding milk replacer containing 5% bovine or porcine plasma to calves containing 16.8% (DM) immunoglobulins resulted in decreased morbidity and mortality due to enteric disease ([@bib28]). Other non-IgG factors in the colostrum supplement (e.g., epidermal growth factor and tumor necrosis factor-α) that protect the gut through mucosal growth and healing ([@bib25]; [@bib12]; [@bib9]) may also have contributed to the decrease in diarrhea. A comparison of feeding serum-derived blood plasma containing immunoglobulins and colostrum or colostrum supplement could further elucidate the components in the colostrum that are critical to optimize calf gut health.

Low-weight calves had more diarrhea days than heavier calves. All study calves were Holstein dairy source calves and there was no significant difference in passive transfer status to explain the increased diarrhea in low-weight calves. The increased diarrhea may be a result of low-weight calves being fed more milk in relation to BW (all calves received the same volume of milk replacer), resulting in greater fecal output than the heavier calves ([@bib21]). The increased rate of diarrhea on ranches A and B compared with C is likely explained by the greater numbers of calves on ranch C that died acutely, before observed signs of disease.

ADG and Grain Consumption
-------------------------

The colostrum-supplemented calves gained more weight by 28 d of age compared with control calves, but by 60 d of age there was no difference in ADG between the groups. The early weight gain difference for the CS calves may be due to additional nutrients from the colostrum supplement ([@bib20]) and the observed increased grain consumption in this group. The placebo supplemented group also had greater grain consumption compared with controls, but the ADG at 28 d was not significantly different from controls. The increased grain intake in calves receiving a greater level of nutrition through the milk is in contrast to studies indicating that increased energy intake through the milk replacer leads to decreased grain intake in preweaned calves ([@bib26]; [@bib17]). The greater weight gain in the colostrum-supplemented calves compared with the placebo-supplemented and control calves may be because of lower rates of morbidity. Diseases causing inflammation resulting in the release of cytokines can activate homeorhetic responses to direct nutrients from tissue deposition (i.e, weight gain) toward immunologic defense functions ([@bib13]). The ADG was greater in low-weight calves, most likely because these calves received more milk per kilogram of BW than heavier calves as all calves received similar quantities of milk replacer regardless of arrival weight. The calves with FPT also had lesser weight gains likely because of decreased nutrient utilization and reduced feed intake associated with more disease in these calves compared with calves with APT ([@bib13]). The only significant factors affecting weaning weight were FPT and the calf ranch. Different levels of grain intake on these ranches may partly explain the weaning weight differences. The relatively smaller weight gains in calves on calf ranch C compared with ranches A and B may also have been due to heat stress ([@bib17]).

Conclusions
===========

Although ensuring that calves have APT is the most significant management factor to ensure the health of neonatal calves on calf ranches, colostrum supplementation during the first 2 wk of life in calves was effective in reducing diarrheal disease and the use of antimicrobials. The ADG up to 4 wk of age in colostrum-supplemented calves was significantly greater compared with that in control calves, likely because of a combination of greater energy intake through the liquid feed, increased grain intake, and fewer days with diarrhea. Calf ranch systems need to continue to address problems of colostrum-deprived calves, pathogen load, and environmental stress to successfully raise calves and minimize prophylactic and therapeutic antibiotic use. Supplementing calves with a colostrum product may be a valuable tool to achieve these goals.
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==================
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[^1]: CS = colostrum supplement (70 g of dried colostrum powder) added to milk replacer; PS = placebo supplement (70 g of nutritionally matched supplement without IgG) added to milk replacer; UC = unsupplemented control.

[^2]: APT = adequate passive transfer: IgG ≥1,000 mg/dL; PFPT = partial failure of passive transfer: IgG between (and including) 351 and 999 mg/dL; and FPT = failure of passive transfer: IgG ≤350 mg/dL.

[^3]: Low: ≤38.5 kg; mid: between 38.6 and 45 kg; high: ≥45 kg.

[^4]: CI = confidence interval.

[^5]: CS = colostrum supplement (70 g of dried colostrum powder) added to milk replacer; PS = placebo supplement (70 g of nutritionally matched supplement without IgG) added to milk replacer; UC = unsupplemented control.

[^6]: Low: ≤38.5 kg; mid: between 38.6 and 45 kg; high: ≥45 kg.

[^7]: FPT = failure of passive transfer: IgG ≤350 mg/dL; PFPT = partial failure of passive transfer: IgG between (and including) 351 and 999 mg/dL; and APT = adequate passive transfer: IgG ≥1,000 mg/dL.

[^8]: CS = colostrum supplement (70 g of dried colostrum powder) added to milk replacer; PS = placebo supplement (70 g of nutritionally matched supplement without IgG) added to milk replacer; UC = unsupplemented control.

[^9]: Feed consumption data reported for calves remaining in the study for 28 d.

[^10]: Resp = respiratory disease signs including pulmonary distress noted as thoracic or abdominal hyperventilation, and auscultation indicated congested lungs.

[^11]: CI = confidence interval.

[^12]: CS = colostrum supplement (70 g of dried colostrum powder) added to milk replacer; PS = placebo supplement (70 g of nutritionally matched supplement without IgG) added to milk replacer; UC = unsupplemented control.

[^13]: Low: ≤38.5 kg; mid: between 38.6 and 45 kg; high: ≥45 kg.

[^14]: FPT = failure of passive transfer: IgG ≤350 mg/dL; PFPT = partial failure of passive transfer: IgG between (and including) 351 and 999 mg/dL; and APT = adequate passive transfer: IgG ≥1,000 mg/dL.

[^15]: CI = confidence interval.

[^16]: CS = colostrum supplement (70 g of dried colostrum powder) added to milk replacer; PS = placebo supplement (70 g of nutritionally matched supplement without IgG) added to milk replacer; UC = unsupplemented control.

[^17]: Low: ≤38.5 kg; mid: between 38.6 and 45 kg; high: ≥45 kg.

[^18]: FPT = failure of passive transfer: IgG ≤350 mg/dL; PFPT = partial failure of passive transfer: IgG between (and including) 351 and 999 mg/dL; and APT = adequate passive transfer: IgG ≥1,000 mg/dL.

[^19]: *F*-value = 16.16; df = 8; *P* \< 0.0001; and R^2^ = 0.36.

[^20]: Least squares mean estimate.

[^21]: CI = confidence interval.

[^22]: CS = colostrum supplement (70 g of dried colostrum powder) added to milk replacer; PS = placebo supplement (70 g of nutritionally matched supplement without IgG) added to milk replacer; UC = unsupplemented control.

[^23]: FPT = failure of passive transfer: IgG ≤350 mg/dL; PFPT = partial failure of passive transfer: IgG between (and including) 351 and 999 mg/dL; and APT = adequate passive transfer: IgG ≥1,000 mg/dL.

[^24]: Low: ≤38.5 kg; mid: between 38.6 and 45 kg; high: ≥45 kg.

[^25]: *F*-value = 16.49; df = 8; *P* \< 0.0001; and R^2^ = 0.44.

[^26]: Calves were lost to follow-up in the routine movement of calves within the calf ranches and because of a management change on ranch C that resulted in calves returning to the source farm at 1 mo of age.

[^27]: Least squares mean estimate.

[^28]: CI = confidence interval.

[^29]: CS = colostrum supplement (70 g of dried colostrum powder) added to milk replacer; PS = placebo supplement (70 g of nutritionally matched supplement without IgG) added to milk replacer; UC = unsupplemented control.

[^30]: FPT = failure of passive transfer: IgG ≤350 mg/dL; PFPT = partial failure of passive transfer: IgG between (and including) 351 and 999 mg/dL; and APT = adequate passive transfer: IgG ≥1,000 mg/dL.

[^31]: Low: ≤38.5 kg; mid: between 38.6 and 45 kg; high: ≥45 kg.

[^32]: *F*-value = 20.17; df = 8; *P* \< 0.0001; and R^2^ = 0.42.

[^33]: Least squares mean estimate.

[^34]: CI = confidence interval.

[^35]: CS = colostrum supplement (70 g of dried colostrum powder) added to milk replacer; PS = placebo supplement (70 g of nutritionally matched supplement without IgG) added to milk replacer; UC = unsupplemented control.

[^36]: FPT = failure of passive transfer: IgG ≤350 mg/dL; PFPT = partial failure of passive transfer: IgG between (and including) 351 and 999 mg/dL; and APT = adequate passive transfer: IgG ≥1,000 mg/dL.

[^37]: Low: ≤38.5 kg; mid: between 38.6 and 45 kg; high: ≥45 kg.
